A good example would be the inhibition of enzymatic kinase activity of BCR-ABL fusion protein in chronic myeloid leukemia (CML) with imatinib (Gleevec®) [7]. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.